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Brain volumetric and metabolic correlates of electroconvulsive
therapy for treatment-resistant depression: a longitudinal
neuroimaging study
M Cano1,2, I Martínez-Zalacaín1, Á Bernabéu-Sanz3, O Contreras-Rodríguez1,4, R Hernández-Ribas1,2,4, E Via5, A de Arriba-Arnau1,
V Gálvez6, M Urretavizcaya1,2,4, J Pujol4,7, JM Menchón1,2,4, N Cardoner5 and C Soriano-Mas1,4,8
Recent research suggests that neuroplastic and neuroinflammatory changes may account for the mode of action of
electroconvulsive therapy (ECT), although extant data do not allow for a clear disambiguation between these two hypotheses.
Multimodal neuroimaging approaches (for example, combining structural and metabolic information) may help in clarifying this
issue. Here we aimed to assess longitudinal changes in (i) regional gray matter (GM) volumes and (ii) hippocampal metabolite
concentrations throughout an acute course of bitemporal ECT, as well as (iii) to determine the association between imaging
changes and clinical improvement. We assessed 12 patients with treatment-resistant depression (TRD) at four time points (pre-
treatment, after the first ECT session, after the ninth ECT session and 15 days after ECT course completion) and 10 healthy
participants at two time points, 5 weeks apart. Patients with TRD showed bilateral medial temporal lobe (MTL) and perigenual
anterior cingulate cortex volume increases. Left MTL volume increase was associated with (i) a hippocampal N-acetylaspartate
concentration decrease, (ii) a hippocampal Glutamate+Glutamine concentration increase and (iii) significant clinical improvement.
The observed findings are, in part, compatible with both neuroplastic and neuroinflammatory changes induced by ECT. We
postulate that such phenomena may be interrelated, therefore reconciling the neuroplasticity and neuroinflammatory hypotheses
of ECT action.
Translational Psychiatry (2017) 7, e1023; doi:10.1038/tp.2016.267; published online 7 February 2017
INTRODUCTION
Electroconvulsive therapy (ECT) is a well-established alternative for
treatment-resistant depression (TRD).1 Nevertheless, its mechan-
ism of action remains poorly understood. Recent studies have
used magnetic resonance imaging (MRI) to explore the changes in
brain structure putatively associated with ECT and have consis-
tently reported volume increases in limbic regions such as the
hippocampus, the amygdala or the anterior cingulate cortex
(ACC).2–12
Although recent reports advocated that such ECT-induced
structural changes could result from neurogenesis induction in
neurogenic regions (that is, dentate gyrus13), the extension of
volume increases to other hippocampal subfields and limbic
regions14 suggests that they are likely better understood as
resulting from more general structural neuroplastic changes,
which embrace different molecular mechanisms in addition to
neurogenesis, such as synaptogenesis, gliogenesis or
angiogenesis.15 Likewise, other reports suggested that ECT-
induced structural changes might partially depend on neuroin-
flammatory mechanisms.8,16 It has been shown that ECT may
increase the permeability of the blood–brain barrier,17 possibly
leading to a local swelling of adjacent brain tissue (that is,
vasogenic edema).16
The assessment of brain regional metabolite concentrations
may complement structural studies in ascertaining the neurobio-
logical correlates of ECT. Magnetic resonance spectroscopy (MRS)
studies have shown both decreases and increases of N-acetylas-
partate (NAA) across different regions, such as the ACC, the dorsal
lateral prefrontal cortex or the amygdala after ECT.18–20 Moreover,
four studies have explored ECT-induced NAA changes in the
hippocampus,9,20–22 finding decreases20 or no changes9,21,22 in
NAA concentrations. At the hippocampal level, increases in Cho
(choline-containing) compounds have been also detected in two
studies.21,22 However, despite increases in Glutamate+Glutamine
(Glx) concentrations could result in neuronal swelling and
excitotoxicity,23 which might support the neuroinflammatory
hypothesis of ECT action, this metabolite has been only assessed
in one previous study at the hippocampal level, where a
decrease in Glx concentrations after ECT was observed.20
Conversely, significant Glx increases after ECT have been observed
in the ACC, the dorsal lateral prefrontal cortex or the
amygdala.18,20,24,25
In addition, from a clinical perspective, such neurobiological
mechanisms allegedly accounting for ECT effectiveness have been
ill-related with clinical outcomes. For example, only two studies
have presented findings directly relating structural changes with
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the symptomatic improvement of TRD patients. In these studies,
gray matter (GM) volume increases in the hippocampus10 and the
amygdala7,10 were associated with symptom improvement after
ECT. Moreover, only one MRS study has reported significant
associations between hippocampal Glx concentration decreases
and subgenual anterior cingulate Glx concentration increases and
clinical improvement.20 In the present study, to better characterize
the neurobiological correlates of ECT, we performed a longitudinal
assessment of TRD patients throughout an acute course of
bitemporal ECT (that is, pre-treatment, after the first ECT session,
after the ninth ECT session and 15 days after ECT completion).
Clinical and imaging (structural MRI and MRS) measurements were
obtained in each time point. The specific aims of the study were:
(i) to assess longitudinal changes in regional GM volumes, (ii) to
investigate longitudinal changes in hippocampal metabolite
concentrations and (iii) to study the association between imaging
changes and clinical improvement. On the basis of the previous
literature, we expect to find regional volume increases in limbic
structures after ECT. We also anticipate that hippocampal
metabolite concentrations (specifically, NAA and Glx) will change
after treatment, although we cannot predict the direction of
change. Finally, we expect structural and MRS findings to be
associated with clinical improvement.
MATERIALS AND METHODS
Participants
Twelve inpatients with TRD were consecutively recruited from the Mood
Disorders Inpatient Unit of Bellvitge University Hospital, Barcelona, Spain.
At inclusion, all the patients met criteria for a major depressive episode
according to the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR)26 and the independent evaluation performed by two senior
psychiatrists (MU and NC) using the Structured Clinical Interview for DSM-
IV Axis I Disorders–Clinician Version.27 Inter-rater agreement was 100%. All
the patients underwent a comprehensive clinical assessment before ECT,
including a physical examination, routine blood sampling, EKG and a chest
x-ray. All the patients were under medication, which was kept constant
throughout the ECT protocol. A list of concurrent pharmacological
treatment is provided in Supplementary Table 1.
The control group was made up of 10 subjects matched for age, gender
and years of education. Each healthy control underwent the non-patient
version of the Structured Clinical Interview for DSM-IV Axis I Disorders28 to
exclude any Axis I psychiatric disorders and the use of psychotropic
medication. For both the groups, exclusion criteria included: (i) the
presence or past history of a severe medical or neurological disorder, (ii)
contraindication to MRI scanning or abnormal MRI upon visual inspection
and (iii) a history of ECT during the previous 12 months.
The study was approved by the ethics committee of clinical research
(CEIC) of Bellvitge University Hospital, and was performed in compliance
with national legislation and the principles expressed in the Declaration of
Helsinki. All the participants gave written informed consent after being
provided with a detailed description of the study.
Electroconvulsive therapy
Following our ECT unit protocol and national and international
standards,29–31 all the patients were treated with bifrontotemporal, brief
pulse (0.5–1 ms) ECT, using a Thymatron System IV device (Somatics,
Lake Bluff, IL, USA). Anesthesia was induced with intravenous thiopental
(2–2.5 mg kg− 1) and succinylcholine (0.5 mg kg− 1) was used for muscle
paralysis. The patients were pre-oxygenated and then manually ventilated
during the duration of anesthesia. Initial electrical dose was determined by
the half-age method32 and subsequent dosing was determined according
to seizure morphology adequacy. The psychotropic medications were
maintained unchanged throughout the ECT treatment course.
Study protocol
The patients were scanned four times: 24–48 h before the first ECT session
(MRI1—baseline), 24–48 h after the first ECT session (MRI2—early ECT
effects), 24–48 h after the ninth ECT session (MRI3—intermediate ECT
effects) and 2 weeks after the completion of the ECT course (MRI4—long-
lasting ECT effects). The control subjects were scanned twice, 5 weeks
apart. Moreover, all the patients underwent a weekly clinical assessment
using the Hamilton Rating Scale for Depression (HRSD-21 items).33
MRI and MRS acquisition and preprocessing
All the MR studies were performed in a Philips Achieva 3.0 Tesla magnet
scanner (Philips Healthcare, Best, The Netherlands), equipped with an
eight-channel phased-array head coil provided by the manufacturer to
obtain three-dimensional anatomical images and proton (1H) MR
spectroscopy.
Three-dimensional anatomical images. High-resolution anatomical images
were obtained using a sagittal T1-weighted three-dimensional fast spoiled
gradient sequence. A total of 160 slices were acquired with repetition
time= 8.1 ms; echo time= 3.7 ms; flip angle = 8°, field of view= 240×
240 mm; matrix size 256× 256 pixels, in-plane resolution= 0.94 × 0.94 mm2;
slice thickness = 1 mm.
Structural MRI data were processed on a Microsoft Windows platform
using technical computing software (MATLAB 7.14; The MathWorks, Natick,
MA, USA) and Statistical Parametric Mapping (SPM12; The Welcome
Department of Imaging Neuroscience, London, UK). First, the images were
visually inspected by experienced members of the research team for the
presence of any artifacts preventing further analyses. Subsequent image
preprocessing was performed at the individual level, and consisted of an
initial rigid-body (that is, translations and rotations) within-subject co-
registration to the first scan of the series to ensure good starting estimates.
This was followed by pairwise longitudinal registrations between the
scans from different time points using symmetric diffeomorphic
modeling34 to assess volumetric change across the ECT course. This step
incorporated a bias field correction to minimize the effects of intensity
inhomogeneities on further preprocessing.35 This algorithm generated, for
each image pair, an average image (that is, the average of the MRI images
from the two time points) and a Jacobian difference map (that is, a map of
the regional volume change between the two time points). The average
image was segmented with the New Segment algorithm36 to isolate GM
voxels and, to specifically identify GM volume changes, GM voxels from the
segmented average image were multiplied by the volume change map (so
we focused on longitudinal volume changes of GM regions). Next, we
obtained a specific template of our study sample (in Montreal Neurological
Institute (MNI) space) using a Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra algorithm,37,38 which was used to
spatially normalize the GM volume change maps before between-group
comparisons. Importantly, no modulation (that is, volume restoration) was
performed after the normalization to the MNI template. Finally, the
resultant images were smoothed with an 8 mm full-width at half maximum
isotropic Gaussian Kernel.
1H MR spectroscopy. The spectra were acquired using a single-voxel Point-
Resolved Spectroscopy sequence with TR, 2000 ms; TE, 32 ms and 256
averages. In addition, unsuppressed water scans (19 averages) were
acquired alongside each scan. Total scan duration was 9 min 8 s. A total of
2048 data points were collected over a spectral width of 2000 Hz. The
volume of interest acquired in each participant was adjusted to individual
left hippocampus anatomy. Mean (s.d.) voxel dimensions were 27.9 (3.8)
mm×13.4 (1.7) mm×10.4 (1.6) mm and the total mean volume size 4.0
(1.6) ml. Repositioning accuracy was optimized by use of the Philips
SameScan auto-position tool and visual matching with baseline geometry
in the three orthogonal planes. Shimming and tuning were carried out via
automated procedures before acquisition. Water signal was suppressed
with selective water signal inversion.
The spectra analysis was performed off-line with the use of jMRUI
software (available through the MRUI Project, http://www.mrui.uab.es).39,40
Fitted areas of the resonances of interest were calculated in the water-
suppressed spectrum by using the Advanced Magnetic Resonance
(AMARES) algorithm as described previously.41 Assignment of the
resonances of interest included NAA at 2.02 p.p.m., glutamate and
glutamine (Glx) at 2.35 p.p.m., creatine plus phosphocreatine (Cr) at
3.03 p.p.m. and choline and other trimethylamine-containing compounds
(Cho) at 3.20 p.p.m.42 For spectra quality, minimum values of metabolite
SNR4 10 and unsuppressed water peak linewidth o 8 Hz were used. In
addition, each water-suppressed spectrum was quality checked by visual
inspection to detect artifacts that would adversely affect the quality of the
results such as large baseline distortions, exceptionally broadened
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metabolite peaks, insufficient removal of the water line, large phase errors
and presence of signals originating from outside the voxel.
Statistical analyses
Sociodemographic and clinical data were analyzed with SPSS v.21 (SPSS,
Chicago, IL, USA) using nonparametric tests.
To assess ECT effects on GM volumes, we first performed a whole-brain
voxel-wise volumetric comparison between volume change maps of
patients with TRD and healthy controls in SPM. Importantly, to facilitate the
interpretation of our findings, we exclusively examined changes relative to
baseline. Specifically, we estimated three two-sample t-test models,
corresponding to the analysis of three time-point differences (MRI1–
MRI2, MRI1–MRI3 and MRI1–MRI4). Age and gender were included as
confounding covariates. Statistical significance was set at Po0.05 (two-
sided), family-wise error corrected for multiple comparisons.
Next, we assessed the structural covariance between the regions of
significant longitudinal volume change. Specifically, we extracted the voxel
values from the peak coordinates of the above analyses (representing the
regional volume change) and obtained the correlations between such
longitudinal changes. We used Spearman's ρ correlation coefficients, with
a statistical significance threshold of Po0.05 (two-sided) after Bonferroni
correction for multiple comparisons. These analyses were performed in
SPSS v.21.
A Wilcoxon signed-rank test analysis was used to assess across-time
changes in hippocampal metabolite concentrations. Cross-sectional
between-group differences in this imaging assessment were assessed
with Mann–Whitney U-tests. In addition, the relationship between GM
volume changes (extracted from the peak coordinates of the above
analyses) and hippocampal metabolite concentration changes was
explored using Spearman's ρ correlation coefficients. In such analyses,
we used a statistical significance threshold of Po0.05 (two-sided) after a
Bonferroni correction for multiple comparisons when appropriate. All these
analyses were performed in SPSS v.21.
The association between clinical response and GM volume changes was
assessed using multiple regression analyses. Clinical response, as measured
by the percentage of change in HRSD scores, was included as an
independent predictor in an SPM multiple regression model to evaluate its
effect on regional GM volume changes. Importantly, this analysis was
focused on the pattern of significant results derived from the above whole-
brain regional volume comparison. Age and gender were included as
confounding covariates. Statistical significance was set at Po0.05
(two-sided), family-wise error corrected for multiple comparisons across
all in-mask voxels (that is, using small-volume correction procedures). The
relationship between clinical response and hippocampal metabolite
concentration changes was assessed using Spearman's ρ correlation
coefficients, with a statistical significance threshold of Po0.05 (two-sided)
after Bonferroni correction for multiple comparisons. These last analyses
were performed in SPSS v.21.
RESULTS
Sociodemographic and clinical characteristics
Twelve patients with TRD received an acute bitemporal ECT
course. The mean number of sessions per week (± s.d.) was 2.43
( ±0.38), averaging 11 ECT sessions per patient (mean ECT
sessions ± s.d. = 11.08 ± 1.50). The mean HRSD score (± s.d.) before
ECT initiation was 31.25 (9.21) and the mean HRSD score ( ± s.d.)
after the completion of the ECT was 2.92 (2.54). At the end of the
treatment, all the patients fulfilled clinical response criteria
(reduction 450% in HRSD score) and all but one were in clinical
remission (HRSDo8). Moreover, the reduction in depression
severity (HRSD score) between MRI1 and MRI4 assessments was
significant according to a Wilcoxon signed-rank test (z=−3.062;
P= 0.002). Importantly, this significant reduction in depression
severity was already observed at MRI3 (Wilcoxon signed-rank test,
z=− 3.059; P= 0.002). Sociodemographic and clinical character-
istics of the study samples are summarized in Table 1.
Neuroimaging analyses
Structural MRI. GM volume change from MRI1 to MRI2 did not
significantly differ between the groups. By contrast, in comparison
with healthy controls, from MRI1 to MRI3, TRD patients showed a
significant GM volume increase in: (i) the medial temporal lobe
(MTL), including bilateral amygdala, hippocampus and parahippo-
campal cortex and (ii) the right perigenual anterior cingulate
cortex (rPgACC). In addition, the GM volume increase in the MTL
remained significant at MRI4 in comparison with MRI1. These
results are summarized in Table 2 and Figure 1. At an exploratory
level, we observed that these same regions did also significantly
increase from MRI2 to both MRI3 and MRI4, however, to facilitate
Table 1. Sociodemographic and clinical characteristics of the study samples
Sociodemographic and clinical variablesa Patients with TRD (n=12) Comparison participants (n=10) Statisticb P-value
Age, years: mean (s.d.) 59.17 (8.02) 54.4 (8.37) − 1.454 0.159
Gender, male: n (%) 6 (50) 5 (50) 0 1
Education, years: mean (s.d.) 9.75 (5.91) 12.44 (3.39) − 1.253 0.219
Psychotic symptoms: n (%) 5 (41.7)
Comorbid anxiety disorder: n (%) 3 (25)
Age at onset, years: mean (s.d.) 40.58 (19.00)
Duration of current episode, weeks: mean (s.d.) 61.75 (134.46)
Number episodes: mean (s.d.) 4.08 (2.71)
HRSD1c: mean (s.d.) 31.25 (9.21)
HRSD2: mean (s.d.) 28.50 (9.52)
HRSD3: mean (s.d.) 6.75 (5.17)
HRSD4: mean (s.d.) 2.92 (2.54)






Previous ECT: % 16.7
Abbreviations: ECT, electroconvulsive therapy; HRSD, Hamilton Rating Scale for Depression; MSM, Maudsley Staging Model; TRD, treatment-resistant
depression. aNo significant differences were observed between groups in any of the variables. bMann–Whitney U-test for continuous variables, Χ2 test for
categorical variables. cThis number indicates the time point corresponding to the HRSD score. 1—Score in the first neuroimaging assessment; 2—Score in the
second neuroimaging assessment; 3—Score in the third neuroimaging assessment; and 4—Score in the fourth neuroimaging assessment.
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Table 2. Brain areas showing gray matter volume increases in patients with treatment-resistant depression
x y z t-value P-valueaaFWE (family-wise error)
corrected for multiple comparisons.
Anatomical location
MRI1–MRI3
Left MTL (12 137 voxels) − 26 − 3 − 21 14.92 o0.001 Left amygdala
− 24 − 6 − 23 14.28 o0.001 Left hippocampus
− 21 − 7 − 26 13.36 o0.001 Left parahippocampus
Right MTL (18 120 voxels) 21 0 − 20 13.15 o0.001 Right amygdala
23 − 1 − 20 13.01 o0.001 Right hippocampus
21 2 − 23 13.35 o0.001 Right parahippocampus
8 35 − 5 8.42 o0.001 rPgACC (553 voxels)
MRI1–MRI4
Left MTL (10 985 voxels) − 26 − 4 − 14 12.81 o0.001 Left amygdala
− 26 − 7 − 14 11.85 o0.001 Left hippocampus
− 26 − 7 − 14 11.85 o0.001 Left parahippocampus
Right MTL (15 460 voxels) 23 − 4 − 18 13.81 o0.001 Right amygdala
23 − 6 − 21 14.02 o0.001 Right hippocampus
26 − 13 −26 13.97 o0.001 Right parahippocampus
Abbreviations: MRI, magnetic resonance image; MTL, medial temporal lobe; rPgACC, right perigenual anterior cingulate cortex. x, y, z coordinates are reported
in standard Montreal Neurological Institute (MNI) space.
Figure 1. (a) Volume changes in bilateral MTL (including the bilateral amygdala, hippocampus and parahippocampus) between MRI1 and
MRI3, overlaid on coronal and axial slices in MNI-normalized space. The cluster of significant findings extended to other areas such as the
insula, the striatum or the inferior temporal cortex, although the results on these regions were much less defined and less significant in
relation with findings in the MTL. Left hemisphere is depicted on the left. (b) Volume change in the right perigenual anterior cingulate cortex
(rPgACC) between MRI1 and MRI3, overlaid on a sagittal slice in MNI-normalized space. Volume increases in the right temporal pole (extending
from the cluster depicted in a) may be also appreciated. Color bar represents t-value. MNI, Montreal Neurological Institute; MRI, magnetic
resonance image; MTL, medial temporal lobe.
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the interpretation of our findings and since the first significant
clinical and imaging changes were observed at MRI3, subsequent
imaging analyses were centered on the comparison of this time
point with baseline.
For reference, in Supplementary Material, we provide a baseline
voxel-based morphometry analysis comparing MDD patient group
vs controls before ECT. No significant between-group differences
were observed at the selected significance threshold.
Structural covariance. Interestingly, we observed significant
correlations between the left and right MTL MRI1–MRI3 volume
changes (ρ= 0.699, P= 0.011) and between left MTL and rPgACC
volume changes (ρ= 0.636, P= 0.026). As such, this reflects the
existence of structural covariance in the volume change of these
structures.
1H MR spectroscopy. An example spectrum and fitting is provided
in Supplementary Figure 1. A Wilcoxon signed-rank test on
hippocampal metabolite concentrations revealed that NAA/Cr
ratio significantly decreased after the ninth ECT session (MRI3;
z=− 2.432, P= 0.015), whereas the Glx/Cr ratio increased at a trend
level at this same time point (z=− 1.961, P= 0.050; see Figure 2).
Cho/Cr ratio did not significantly differ between time points.
Likewise, MRS data from healthy controls did not differ between
time points. Moreover, the between-group (patient vs control)
comparison of pre- and post-ECT MRS assessments did not detect
any significant difference for any metabolite.
Importantly, in the patient group, we observed a significant
correlation between the left hippocampus volume change and the
hippocampal NAA/Cr ratio change (ρ=− 0.706, P= 0.010), as well
as a trend level correlation between the left hippocampus volume
change and the hippocampal Glx/Cr ratio change (ρ= 0.629,
P= 0.028, nonsignificant after Bonferroni correction for multiple
comparisons; see Figure 3a).
Relationship with clinical change. An SPM multiple regression
analysis including clinical response from MRI1 to MRI3 as the
independent predictor and the voxel-wise MRI1–MRI3 GM volume
change within the cluster of significant findings from the previous
structural comparisons as the dependent variable (that is, using
small-volume correction procedures) revealed a significant
(t= 7.26; P= 0.047) positive association between clinical improve-
ment and regional GM volume increase in the left MTL (x=− 39,
y=− 12, z=− 14; see Figure 3b).
Conversely, using Spearman correlation analyses in SPSS, we
observed that metabolite concentrations in the hippocampus
were not related with clinical improvement.
DISCUSSION
To our knowledge, this is the first longitudinal study evaluating
brain changes throughout the course of an acute bitemporal
ECT protocol in patients with TRD by means of different
neuroimaging approaches (that is, structural longitudinal voxel-
wise analyses and magnetic resonance spectroscopy). Specifically,
we observed regional volume increases in the MTL and the
rPgACC after ECT, as well as an association of left MTL volume
increase with a hippocampal NAA/Cr concentration decrease
and a hippocampal Glutamate+Glutamine (Glx/Cr) concentration
increase. Likewise, left MTL volume increase was associated with
clinical improvement.
Our structural findings concur with previous GM volume studies
reporting significant volume increases in these same areas after
ECT.2–12 Indeed, these brain regions have consistently been cited
as being critical in accounting for depressive symptomatology and
disease remission in prevailing neurobiological models of
depression.43,44 Interestingly, volume increases in the left and
right MTL were significantly correlated, and we also observed a
correlation between volume increases in the left MTL and the
rPgACC.
These results suggest the existence of ECT-induced structural
covariance (that is, volume correlation between distant brain
regions) between these structures. Indeed, structural covariance
may rely on structural neuroplasticity,45,46 and, therefore, the
findings from our study (that is, more significant changes in the
MTL than in the rPgACC and structural covariance between these
structures) may indicate that the molecular-level mechanisms of
ECT action are probably similar across different brain regions,
differing in their magnitude as the distance from the energy
source increases. Nevertheless, according to this idea, it remains to
be established why structural effects are only observed in limbic
structures and not in neocortical regions, closer to the electrode
location. In this sense, however, it is important to highlight that
structural plasticity is much more frequently observed in limbic
regions than in the prefrontal, motor and sensory cortices.47–49
Notwithstanding the above ideas on the link between ECT and
structural plasticity, it should be noted that while hippocampal
neurogenesis and other forms of neural plasticity have consis-
tently shown a positive effect on learning and memory
capacity,50–52 ECT is undoubtedly associated with significant
impairments in memory and executive functions.53,54 Importantly,
hippocampal volume increases in our subjects were related to an
NAA/Cr ratio decrease and a trend-level Glx/Cr ratio increase. As
NAA levels are considered to be associated with healthy neural
function,55 such NAA decreases seem to indicate a significant ECT-
induced neural malfunction at the hippocampal level, which
would be in agreement with the above-mentioned cognitive side-
effects of ECT. In accordance with our findings, one previous study
Figure 2. (a) Individual hippocampal NAA/Cr ratio change between MRI1 and MRI3 in patients with TRD. (b) Individual hippocampal Glx/Cr
ratio change between MRI1 and MRI3 in patients with TRD. Cr, creatine plus phosphocreatine; Glx, Glutamate+Glutamine; MRI, magnetic
resonance image; NAA, N-acetylaspartate.
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has also identified hippocampal NAA concentration decreases
after ECT.20 By contrast, three other studies identified no
significant changes in hippocampal NAA concentration, although
these studies were performed in 1.5T magnets, which provide a
worse signal-to-noise ratio for detecting metabolite
concentrations,21,22 or acknowledged low-quality spectra for the
hippocampal region.9 The combination of hippocampal NAA
concentration decrease with a regional volume increase may
suggest that ECT-induced changes are due to neuronal swelling or
of non-neural origin (for example, angiogenesis). These two
options are discussed below.
Regarding Glx increases, it is important to emphasize that, as
opposed to previous studies focused on the ACC, the dorsal lateral
prefrontal cortex or the amygdala,18,20,24,25 we did not observe a
decreased Glx/Cr ratio in our TRD patients before treatment
initiation. Therefore, our results do not seem to support the idea
that Glx increases were a consequence of an ECT-induced
normalization in hippocampal Glx levels. They may be better
interpreted within the framework of the neuroinflammatory
hypothesis of ECT action.8,16 Indeed, it is well known that
excessive glutamate levels may lead to neuronal swelling,
secondary to the influx of cations and water.23 In addition,
although neuroinflammation has been typically associated with
ECT cognitive side-effects,16 recent research suggests that in TRD
patients undergoing neurosurgery for implanting a deep brain
stimulation electrode in the subgenual ACC, early clinical
improvement (that is, before the actual initiation of the deep
brain stimulation treatment) was associated with regional
neuroinflammation and attenuated by anti-inflammatory treat-
ment (that is, NSAIDs).56 Therefore, our findings suggest the
existence of a common neurobiological mechanism accounting
for ECT-induced clinical improvement and cognitive side-effects.
However, contrary to our results, a recent study reported
hippocampal Glx concentration increases at baseline that
were reduced after ECT.20 Nevertheless, these findings were
exclusively observed in the left hippocampus, while most
patients received a right unilateral treatment. In this sense, it is
well known that current density in unilateral ECT is substantially
larger in the ipsilateral than in the contralateral hemisphere.57
Therefore, further research is warranted to better characterize and
understand the contralateral effects of unilateral treatment
protocols.
In addition, besides the direct link with neuroinflammation, Glx
increases may also boost angiogenesis to satisfy putative
subsequent increases in metabolic demand, which may in turn
lead to an increase in the permeability of the blood–brain barrier17
and finally to a local swelling of the adjacent brain tissue.16
Importantly, hippocampal angiogenesis has previously been
postulated as a candidate neurobiological correlate of ECT
mechanism of action in pre-clinical research.58 Insofar angiogen-
esis may be considered a form of neuroplasticity,10,15 our findings
reconcile the neuroplasticity and neuroinflammatory hypotheses
of ECT action. Furthermore, other neuroplasticity mechanisms,
such as synaptogenesis, have been shown to be induced after
ketamine administration, which is supposed to increase glutamate
neurotransmission.59
Regarding the relationship between our imaging results and
clinical improvement, it seems that only structural changes in the
MTL, but not in the rPgACC, were significantly associated with
symptom reduction. We think these results give further support to
Figure 3. (a) Scatter plots depicting the relationship between regional gray matter (GM) volume change (adjusted values) in the left
hippocampus and hippocampal NAA/Cr ratio (left) and Glx/Cr ratio (right) changes. (b) Scatter plot depicting the relationship between
regional GM volume change (adjusted values) in the left medial temporal lobe (MTL) and clinical response (percentage of HRSD reduction)
between MRI1 and MRI3. Statistical significance of the correlation held after excluding the subject with the lowest values in the two variables.
Cr, creatine plus phosphocreatine; Glx, Glutamate+Glutamine; HRSD, Hamilton Rating Scale for Depression; MRI, magnetic resonance image;
NAA, N-acetylaspartate.
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the above-mentioned idea of a proportional decrease of ECT
effect with increasing distance from the electrode. Moreover, the
lack of a direct association between our metabolic results and
clinical improvement may also imply that NAA and Glx changes
only partially account for ECT-induced changes at the molecular
level. Other molecular routes such as those involving glial-
fibrillary-acidic-protein and p11 expression56 should be explored
in further research. However, it should be noted that we observed
an indirect association between metabolic changes and clinical
improvement through volumetric change. Therefore, further
analyses with other statistical approaches such as structural
equation modeling are warranted to ascertain as to what extent
the metabolic changes observed here may be indirectly associated
with clinical improvement. Finally, the lateralization of our
correlation between imaging changes and clinical improvement
to the left hemisphere seems to partially account for the
previously described superiority of bilateral ECT in front of right
unilateral approaches in terms of clinical response.60–62
This study has a number of limitations. First, given the small
number of patients included, the results should be considered
preliminary and, therefore, replication with a larger sample is
warranted. Nevertheless, our sample was carefully characterized
with weekly clinical assessments and four multimodal neuroima-
ging assessments covering the entire course of the treatment,
which allowed for a comprehensive characterization of different
neurobiological changes and their association with clinical
response. Likewise, our results should not necessarily generalize
to patient samples undergoing different ECT protocols (for
example, unilateral treatments). Finally, we cannot determine
what effect, if any, concurrent pharmacological treatment had on
our findings, although in an attempt to minimize this confounding
effect, pharmacological treatment was not modified throughout
the entire ECT course. Importantly, we did not observe any
structural or metabolic differences between patient and control
groups in pre-ECT comparisons. In this sense, it should be noted
that although pharmacological treatment with selective serotonin
reuptake inhibitors has been related with the induction of neural
plasticity,63 neuroinflammatory and volumetric changes in limbic
regions have been seldom reported after successful pharmacolo-
gical trials.64 This seems to suggest that these latter effects may be
predominantly observed after ECT, therefore providing a specific
clinical benefit to patients with TRD.
In conclusion, both neural plasticity and neuroinflammation
may be induced by ECT and partially account for its clinical
effectiveness. The nature of the changes seems to be similar
across different brain regions, although the magnitude of the
effects may decrease as the distance from the energy source rises.
Our results also indicate that structural, but not metabolic,
changes in the left medial temporal lobe are the best neuroima-
ging biomarkers of ECT-induced clinical response in TRD. Further
research is needed to ascertain whether a common neurobiolo-
gical underpinning may account for both positive and negative
consequences of ECT.
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